Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 609-618
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.01.086

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Popat, S.
Right arrow Articles by Houlston, R.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Popat, S.
Right arrow Articles by Houlston, R.S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis

S. Popat, R. Hubner, R.S. Houlston

From the Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK

Address reprint requests to Sanjay Popat, MRCP, PhD, Institute of Cancer Research, Brookes Lawley Building, Sutton, Surrey SM2 5NG, UK; e-mail: sanjay.popat{at}icr.ac.uk

PURPOSE: A number of studies have investigated the relationship between microsatellite instability (MSI) and colorectal cancer (CRC) prognosis. Although many have reported a better survival with MSI, estimates of the hazard ratio (HR) among studies differ. To derive a more precise estimate of the prognostic significance of MSI, we have reviewed and pooled data from published studies.

METHODS: Studies stratifying survival in CRC patients by MSI status were eligible for analysis. The principal outcome measure was the HR. Data from eligible studies were pooled using standard techniques.

RESULTS: Thirty-two eligible studies reported survival in a total of 7,642 cases, including 1,277 with MSI. There was no evidence of publication bias. The combined HR estimate for overall survival associated with MSI was 0.65 (95% CI, 0.59 to 0.71; heterogeneity P = .16; I2 = 20%). This benefit was maintained restricting analyses to clinical trial patients (HR = 0.69; 95% CI, 0.56 to 0.85) and patients with locally advanced CRC (HR = 0.67; 95% CI, 0.58 to 0.78). In patients treated with adjuvant fluorouracil (FU) CRCs with MSI had a better prognosis (HR = 0.72; 95% CI, 0.61 to 0.84). However, while data are limited, tumors with MSI derived no benefit from adjuvant FU (HR = 1.24; 95% CI, 0.72 to 2.14).

CONCLUSION: CRCs with MSI have a significantly better prognosis compared to those with intact mismatch repair. Additional studies are needed to further define the benefit of adjuvant chemotherapy in locally advanced tumors with MSI.

Supported by the UK Department of Health (S.P.) and grants from Cancer Research UK and the Association for International Cancer Research (R.S.H.).

Authors’ disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
JCOHome page
N. D. Kauff
ATR Mutations in Endometrial Cancer: A Window Into the Role of Mismatch Repair Defects
J. Clin. Oncol., July 1, 2009; 27(19): 3077 - 3078.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ogino, K. Nosho, N. Irahara, S. Kure, K. Shima, Y. Baba, S. Toyoda, L. Chen, E. L. Giovannucci, J. A. Meyerhardt, et al.
A Cohort Study of Cyclin D1 Expression and Prognosis in 602 Colon Cancer Cases
Clin. Cancer Res., July 1, 2009; 15(13): 4431 - 4438.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
G. DES GUETZ, B. UZZAN, P. NICOLAS, O. SCHISCHMANOFF, G.-Y. PERRET, and J.-F. MORERE
Microsatellite Instability does not Predict the Efficacy of Chemotherapy in Metastatic Colorectal Cancer. A Systematic Review and Meta-analysis
Anticancer Res, May 1, 2009; 29(5): 1615 - 1620.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Paya, C. Alenda, L. Perez-Carbonell, E. Rojas, J.-L. Soto, C. Guillen, A. Castillejo, V. M. Barbera, A. Carrato, A. Castells, et al.
Utility of p16 Immunohistochemistry for the Identification of Lynch Syndrome
Clin. Cancer Res., May 1, 2009; 15(9): 3156 - 3162.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al.
Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway
Clin. Cancer Res., April 15, 2009; 15(8): 2829 - 2839.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
M. M. Bertagnolli, D. Niedzwiecki, C. C. Compton, H. P. Hahn, M. Hall, B. Damas, S. D. Jewell, R. J. Mayer, R. M. Goldberg, L. B. Saltz, et al.
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
J. Clin. Oncol., April 10, 2009; 27(11): 1814 - 1821.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. M. Bertagnolli, R. S. Warren, D. Niedzwiecki, E. Mueller, C. C. Compton, M. Redston, M. Hall, H. P. Hahn, S. D. Jewell, R. J. Mayer, et al.
p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803
Clin. Cancer Res., March 15, 2009; 15(6): 2116 - 2122.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
S. Ogino, K. Nosho, G. J Kirkner, T. Kawasaki, J. A Meyerhardt, M. Loda, E. L Giovannucci, and C. S Fuchs
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Gut, January 1, 2009; 58(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. N. Jorissen, L. Lipton, P. Gibbs, M. Chapman, J. Desai, I. T. Jones, T. J. Yeatman, P. East, I. P.M. Tomlinson, H. W. Verspaget, et al.
DNA Copy-Number Alterations Underlie Gene Expression Differences between Microsatellite Stable and Unstable Colorectal Cancers
Clin. Cancer Res., December 15, 2008; 14(24): 8061 - 8069.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ogino, G. J. Kirkner, K. Nosho, N. Irahara, S. Kure, K. Shima, A. Hazra, A. T. Chan, R. Dehari, E. L. Giovannucci, et al.
Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer
Clin. Cancer Res., December 15, 2008; 14(24): 8221 - 8227.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Ogino, K. Nosho, J. A. Meyerhardt, G. J. Kirkner, A. T. Chan, T. Kawasaki, E. L. Giovannucci, M. Loda, and C. S. Fuchs
Cohort Study of Fatty Acid Synthase Expression and Patient Survival in Colon Cancer
J. Clin. Oncol., December 10, 2008; 26(35): 5713 - 5720.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. L. Moulder, W. F. Symmans, D. J. Booser, T. L. Madden, C. Lipsanen, L. Yuan, A. M. Brewster, M. Cristofanilli, K. K. Hunt, T. A. Buchholz, et al.
Phase I/II Study of G3139 (Bcl-2 Antisense Oligonucleotide) in Combination with Doxorubicin and Docetaxel in Breast Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7909 - 7916.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
F. Pages, J. Galon, and W. H. Fridman
The essential role of the in situ immune reaction in human colorectal cancer
J. Leukoc. Biol., October 1, 2008; 84(4): 981 - 987.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
I Zlobec, L Terracciano, L Tornillo, U Gunthert, T Vuong, J R Jass, and A Lugli
Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer
Gut, October 1, 2008; 57(10): 1413 - 1419.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
R. A. Meguid, M. B. Slidell, C. L. Wolfgang, D. C. Chang, and N. Ahuja
Is There a Difference in Survival Between Right- Versus Left-Sided Colon Cancers?
Ann. Surg. Oncol., September 1, 2008; 15(9): 2388 - 2394.
[Abstract] [Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
I Zlobec and A Lugli
Prognostic and predictive factors in colorectal cancer
Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
A Walther, R Houlston, and I Tomlinson
Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis
Gut, July 1, 2008; 57(7): 941 - 950.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. Zlobec, K. Baker, L. M. Terracciano, and A. Lugli
RHAMM, p21 Combined Phenotype Identifies Microsatellite Instability-High Colorectal Cancers with a Highly Adverse Prognosis
Clin. Cancer Res., June 15, 2008; 14(12): 3798 - 3806.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
B. Pasche
Familial Colorectal Cancer: A Genetics Treasure Trove for Medical Discovery
JAMA, June 4, 2008; 299(21): 2564 - 2565.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. J. French, D. J. Sargent, L. J. Burgart, N. R. Foster, B. F. Kabat, R. Goldberg, L. Shepherd, H. E. Windschitl, and S. N. Thibodeau
Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer
Clin. Cancer Res., June 1, 2008; 14(11): 3408 - 3415.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
I Zlobec and A Lugli
Prognostic and predictive factors in colorectal cancer
J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
K. Imai and H. Yamamoto
Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics
Carcinogenesis, April 1, 2008; 29(4): 673 - 680.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
S. Ogino and A. Goel
Molecular Classification and Correlates in Colorectal Cancer
J. Mol. Diagn., January 1, 2008; 10(1): 13 - 27.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. A. Newcomb, Y. Zheng, V. M. Chia, L. M. Morimoto, V. P. Doria-Rose, A. Templeton, S. N. Thibodeau, and J. D. Potter
Estrogen Plus Progestin Use, Microsatellite Instability, and the Risk of Colorectal Cancer in Women
Cancer Res., August 1, 2007; 67(15): 7534 - 7539.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Malesci, L. Laghi, P. Bianchi, G. Delconte, A. Randolph, V. Torri, C. Carnaghi, R. Doci, R. Rosati, M. Montorsi, et al.
Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer
Clin. Cancer Res., July 1, 2007; 13(13): 3831 - 3839.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
R. A. Hubner, S. Lubbe, I. Chandler, and R. S. Houlston
MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer
Hum. Mol. Genet., May 1, 2007; 16(9): 1072 - 1077.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
J J L Wong, N J Hawkins, and R L Ward
Colorectal cancer: a model for epigenetic tumorigenesis
Gut, January 1, 2007; 56(1): 140 - 148.
[Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
J M Carethers
Authors' reply.
Gut, December 1, 2006; 55(12): 1819 - 1819.
[Full Text] [PDF]


Home page
GutHome page
R Jover, A Castells, X Llor, and M Andreu
Authors' reply.
Gut, December 1, 2006; 55(12): 1819 - 1820.
[Full Text] [PDF]


Home page
JCOHome page
G. Y. Locker, S. Hamilton, J. Harris, J. M. Jessup, N. Kemeny, J. S. Macdonald, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr
ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
J. Clin. Oncol., November 20, 2006; 24(33): 5313 - 5327.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
A S-Y Leong and T Y-M Leong
Newer developments in immunohistology.
J. Clin. Pathol., November 1, 2006; 59(11): 1117 - 1126.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
J M Carethers
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Gut, June 1, 2006; 55(6): 759 - 761.
[Full Text] [PDF]


Home page
GutHome page
R Jover, P Zapater, A Castells, X Llor, M Andreu, J Cubiella, V Pinol, R M Xicola, L Bujanda, J M Rene, et al.
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
Gut, June 1, 2006; 55(6): 848 - 855.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Lanza, R. Gafa, A. Santini, I. Maestri, L. Guerzoni, and L. Cavazzini
Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients
J. Clin. Oncol., May 20, 2006; 24(15): 2359 - 2367.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
P. Benatti, R. Gafa, D. Barana, M. Marino, A. Scarselli, M. Pedroni, I. Maestri, L. Guerzoni, L. Roncucci, M. Menigatti, et al.
Microsatellite Instability and Colorectal Cancer Prognosis
Clin. Cancer Res., December 1, 2005; 11(23): 8332 - 8340.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online